CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
Last trade$0.3434
Day change-$0.0336 (-8.91%)
Day range$0.343 – $0.392
Volume296,348
Market cap$0M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$386.79K
Price / earnings
—
Price / book
0×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.02×
Profitability
Earnings per share
-$36.50
Return on assets
-29.32%
Return on equity
-36.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
0.13×
Quick ratio
0.13×
Cash ratio
0.03×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CDT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.7M
$2.88M
$20.41M
$5.5M
$3.09M
$2.7M
$3.38M
$2.72M
Research and development
$302K
$778K
$746K
$1.53M
$1.86M
$916K
$132K
$3.09M
Total operating expenses
$3M
$3.66M
$21.16M
$7.03M
$4.95M
$3.62M
$3.51M
$5.81M
Operating income
-$3M
-$3.66M
-$21.16M
-$7.03M
-$4.95M
-$3.62M
-$3.51M
-$5.81M
Interest expense
-$17K
-$49K
$0
$0
-$57K
-$176K
$0
$0
Income before taxes
-$4.64M
-$4.06M
-$21.33M
-$7.12M
-$6.03M
-$4.75M
-$2.41M
-$6.46M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.64M
-$4.06M
-$21.33M
-$7.12M
-$6.03M
-$4.75M
-$2.41M
-$6.46M
Net income attributable to common shareholders
-$4.64M
-$4.06M
-$21.33M
-$7.12M
-$6.03M
-$4.75M
-$2.41M
-$6.46M
EBITDA
-$3.31M
-$3.34M
-$20.84M
-$7.65M
-$5.32M
-$3.24M
-$3.51M
-$5.37M
Basic earnings per share
-$4,355.00
-$27,800.00
-$1,017,788.99
-$1,645,000.00
-$5,470,055.00
-$18,351,350.00
-$13,498,693.89
-$111,197,500.00
Diluted earnings per share
-$4,355.00
-$27,800.00
-$1,017,788.99
-$1,645,000.00
-$5,470,055.00
-$18,351,350.00
-$13,498,693.89
-$111,197,500.00
Recent news
Company coverage with links to the original publishers.
CDT Equity Inc. (Nasdaq: CDT) announced 13.7 million shares outstanding as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company confirmed it no longer has outstanding deficiencies with Nasdaq following recent share issuances and corporate actions. CDT, a data-driven biopharmaceutical development company, reported stockholders' equity of approximately $103 million as of June 30, 2026.
CDT Equity Inc. announced the development of new solid forms and crystal structures of its existing drug compounds with improved stability, solubility, and manufacturability. The company has filed patents for new therapeutic uses identified through AI-driven analysis, targeting underserved patient populations. CDT plans to advance these findings through laboratory models and pursue licensing partnerships, aiming to create a differentiated, patent-protected portfolio with reduced scientific risk.
CDT Equity Inc. (Nasdaq: CDT) announced a SAFE note investment in Pep'd Inc., a US-based peptide telehealth company, to gain exposure to the growing peptide therapeutics market projected to reach $294.6 billion by 2033. The investment leverages AI-enabled approaches for peptide development and combines telehealth with research capabilities. Pep'd is controlled by CDT's CEO Dr. Andrew Regan.
CDT Equity (NASDAQ:CDT) shares rose 14.71% to $4.68 on Monday despite the health care sector declining 2.63% over the past 30 days. The rally comes after the biopharmaceutical company disclosed a widened net loss of $39.1 million for 2025 and filed a non-timely 10K. Technical analysis shows the stock trading 49.1% below its 20-day moving average and 84.6% below its 100-day moving average, with the stock down 99.83% over the past 12 months. The company is set to report earnings on April 24.
CDT Equity Inc. (NASDAQ:CDT) announced multiple strategic initiatives to enhance shareholder value, including its 20% equity stake acquisition in Sarborg AI for $115 million, continued development of its pharmaceutical portfolio with AstraZeneca-licensed assets, and evaluation of capital markets initiatives to strengthen financial flexibility.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.